---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002149"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2025-04-10T23:59:59+00:00"
generated_at: "2026-05-23T16:50:56.650112+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience receives Nasdaq bid-price deficiency; CFO Cote resigns effective May 12

## Summary
- Nasdaq notified HBIO on April 4, 2025 of non-compliance with $1.00 minimum bid price; 180-day cure through Oct 1, 2025.
- CFO Jennifer Cote resigns effective upon filing Q1 10-Q (due by May 12, 2025); resignation not due to any disagreement.
- Mark Frost appointed interim CFO and Treasurer effective on Cote's departure; base salary $320k, $50k bonus tied to full debt repayment.
- Frost receives 100k time-based RSUs vesting in one year, with pro-rata vesting if terminated without cause.
- If not cured, HBIO may transfer to Nasdaq Capital Market for second 180-day period or face delisting.

## SEC filing metadata
- accession: 0001171843-25-002149
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2025-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184325002149/0001171843-25-002149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184325002149/f8k_041025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002149
- JSON: https://secwatch.observer/filing/0001171843-25-002149.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002149.txt

## Key facts
- Listing & Compliance Notices
  HARVARD BIOSCIENCE INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: April 4, 2025, Harvard Bioscience, Inc. (the “Company”) received written notice (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the d
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184325002149/0001171843-25-002149-index.htm
- Executive change
  Mark Frost was appointed as Interim Chief Financial Officer and Treasurer at HARVARD BIOSCIENCE INC.
  - Action: appointed
  - Role: Interim Chief Financial Officer and Treasurer
  source text: On April 10 2025, the Board of Directors of the Company appointed Mark Frost to serve as Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignation (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184325002149/0001171843-25-002149-index.htm
- Executive change
  Jennifer Cote resigned as Chief Financial Officer and Treasurer at HARVARD BIOSCIENCE INC.
  - Action: resigned
  - Role: Chief Financial Officer and Treasurer
  source text: On April 7, 2025, Jennifer Cote notified the Company of her resignation as Chief Financial Officer and Treasurer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184325002149/0001171843-25-002149-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.